VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
VRDN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
VRDNViridian Therapeutics, Inc.
$30.12$2.7B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. VRDN
  4. Financial Ratios

Viridian Therapeutics, Inc. (VRDN) Financial Ratios

Latest Ratios: P/E Ratio -7.5x · EV/EBITDA N/A · ROE -49.2%. (2012–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

VRDN Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Market Cap$2.7B$2.6B$1.3B$975M$937M$236M$59M$15M$90M$201M$54M
Enterprise Value$2.5B$2.5B$1.2B$893M$787M$194M$13M$-1500523$67M$163M$52M
P/E Ratio →-7.53——————————
P/S Ratio103.0337.254309.193104.38528.9379.5355.733.3710.7050.1416.25
P/B Ratio3.543.651.942.212.371.260.490.951.755.21—
P/FCF———————————
P/OCF———————————

P/E links to full P/E history page with 30-year chart

VRDN EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
EV / Revenue—34.974049.262843.93444.1065.6012.45-0.348.0340.7715.56
EV / EBITDA———————————
EV / EBIT———————————
EV / FCF———————————

VRDN Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Gross Margin100.0%100.0%100.0%100.0%100.0%100.0%-2595.6%100.0%-262.8%-390.2%23.6%
Operating Margin-512.9%-512.9%-99018.2%-81035.0%-7579.2%-2690.8%-10512.4%-941.0%-394.5%-662.8%-374.8%
Net Profit Margin-483.6%-483.6%-89387.1%-75711.5%-7329.2%-2680.2%-10544.3%-938.6%-390.0%-662.3%-379.8%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
ROE-49.2%-49.2%-48.5%-56.8%-44.6%-51.6%-163.1%-124.8%-72.8%-138.9%-251.4%
ROA-41.7%-41.7%-43.8%-51.4%-40.7%-47.4%-137.1%-86.9%-55.1%-93.5%-147.7%
ROIC-47.3%-47.3%-47.0%-63.1%-51.5%-54.1%-224.3%-222.9%-165.3%-2008.0%—
ROCE-47.7%-47.7%-51.6%-58.8%-45.4%-51.3%-156.9%-105.6%-61.3%-110.0%-247.5%

VRDN Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Debt / Equity0.070.070.030.050.010.010.000.530.200.26—
Debt / EBITDA———————————
Net Debt / Equity—-0.22-0.12-0.19-0.38-0.22-0.38-1.05-0.43-0.97—
Net Debt / EBITDA———————————
Debt / FCF———————————
Interest Coverage-68.24-68.24-87.62-127.71-266.23-26470.00-79.76-49.15-36.46-68.22-132.41

Net cash position: cash ($212M) exceeds total debt ($51M)

VRDN Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Current Ratio12.6512.6515.4318.2612.7314.6812.142.929.7113.310.93
Quick Ratio12.6512.6515.4318.2612.9314.6812.142.929.7113.310.91
Cash Ratio12.3712.3714.9917.9212.7314.4411.962.649.2812.170.73
Asset Turnover—0.080.000.000.000.010.010.150.130.080.78
Inventory Turnover——————————39.81
Days Sales Outstanding———118.5721.0155.56—8.841.04132.7657.31

VRDN Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Dividend Yield———————————
Payout Ratio———————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Earnings Yield———————————
FCF Yield———————————
Buyback Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.3%
Total Shareholder Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.3%
Shares Outstanding—$85M$68M$45M$32M$12M$4M$2M$2M$1M$721410

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetAdequate
Cash FlowBurning
Top Statement Risk

Cash runway versus Phase 3 funding

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Premium Pricing Ahead of Commercial Proof

Based on reported figures, VRDN trades at a P/S of 36.19 and P/B of 3.35 with a negative trailing P/E of -8.58, a multiple structure that prices in future Lumvoa commercial success rather than current earnings power or cash generation.

Compared with its own history, the price-to-sales multiple appears elevated because the revenue denominator is driven by lumpy milestone recognition rather than recurring product sales. Relative to peers such as IMVT at 6.53x P/B and KYMR at 7.04x, VRDN's 3.35x P/B looks comparatively restrained, suggesting the market is not yet assigning a full premium on book value. Investors should monitor whether early Lumvoa revenue growth can justify the growth expectations embedded in these multiples.

Milestone Revenue Masks Operating Losses

As reported in financial statements, VRDN posted a 2026Q3 operating margin of -4.0% but operating margins of -444.6% and -823.9% in the prior two quarters, showing that single-quarter profitability readings are highly sensitive to milestone timing.

The 94.1% to 100% gross margins reflect milestone accounting without offsetting manufacturing costs, so they carry little analytical weight for true earning power. Operating losses scaled with R&D spend, as the trailing operating margin of -512.9% indicates a cost base far exceeding recognized revenue. The more informative measure of earning power is the sustained operating loss of roughly $100M to $125M per quarter, which warrants close tracking as Lumvoa scales.

Negative Returns Reflect Continued Capital Consumption

According to recent filings, VRDN's ROE ranged from -6.8% to -19.6% and ROIC from -7.7% to -20.1% across the ten quarters, indicating returns on invested capital that have been consistently negative rather than compounding.

The pattern shows no sustained improvement in ROIC despite the asset base expanding from $585.7M to $1.0B, suggesting new capital is funding R&D rather than productive earning assets. Return metrics are driven primarily by the operating loss rather than by capital efficiency, so the margin problem and the capital problem are effectively the same problem. Until operating losses narrow materially, return metrics are unlikely to turn positive.

Debt Rising From a Low Base

Based on EDBL's reported figures, VRDN's debt-to-equity ratio climbed from 0.04 a year earlier to 0.42 at 2026Q3, with total debt of $243.3M, a rise that is modest in absolute terms but steep in relative direction.

Interest coverage is deeply negative at -10.94x in 2026Q3 and has been negative throughout the reported window, meaning current earnings provide no debt service capacity and obligations appear to be met from the cash balance. The rapid increase in leverage appears to coincide with balance sheet expansion funded externally, so debt service expectations should be tracked against reported quarterly cash outflows. The absence of a reported debt maturity profile in the supplied data limits assessment of refinancing exposure.

Strong Current Ratio Versus Burn Reality

As reported in financial statements, VRDN's current ratio of 14.46 at 2026Q3 and $172.9M in cash appear strong on paper, but quarterly operating outflows of roughly $90M to $125M suggest the liquidity buffer could be consumed within a few quarters.

The current ratio of 14.46 is driven by short-term assets that likely include cash and clinical-stage receivables, and it does not account for planned Phase 3 spending on THRIVE and THRIVE-2. Under a stress scenario where milestone revenue fails to recur, the cash position would likely require additional equity raises to maintain trial timelines. This suggests the liquidity position warrants further investigation against the company's disclosed runway guidance, which is not included in the supplied data.

Price-to-Sales Misreads Milestone-Driven Revenue

Based on reported figures, the 36.19 P/S multiple is most commonly misapplied to VRDN because revenue is milestone-timed rather than recurring, so the ratio overstates the sales-based premium the market is actually paying for the pipeline.

Applying a sales multiple to a company whose revenue swung from near-zero to $70.6M and back to $25.8M obscures the fact that the market is valuing the Lumvoa franchise and pipeline rather than current sales. A more appropriate lens is cash burn-adjusted enterprise value per dollar of risk-adjusted peak sales, along with runway months from the $172.9M cash balance. This suggests investors should monitor clinical milestones and funding timing rather than anchor on trailing P/S.

Download Financial Ratios Data

Includes 30+ ratios · 14 years · Updated daily

Consensus & Technical Research Suite
Open VRDN Terminal

VRDN Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

VRDN — Frequently Asked Questions

Quick answers to the most common questions about buying VRDN stock.

What is Viridian Therapeutics, Inc.'s P/E ratio?

Viridian Therapeutics, Inc.'s current P/E ratio is -7.5x. This places it at the 50th percentile of its historical range.

What is Viridian Therapeutics, Inc.'s ROE?

Viridian Therapeutics, Inc.'s return on equity (ROE) is -49.2%. The historical average is -111.0%.

Is VRDN stock overvalued?

Based on historical data, Viridian Therapeutics, Inc. is trading at a P/E of -7.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.

What are Viridian Therapeutics, Inc.'s profit margins?

Viridian Therapeutics, Inc. has 100.0% gross margin and -512.9% operating margin.